Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK Other Financing Activities
Financing cash flows not reported separately.
Stryker CorporationNYSE: SYK
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities grows, but more slowly than its trailing trend
Q2 FY2026 other financing activities of $8M (cash outflow) rose 33.3% year over year, behind the +1924.2% change in trailing-twelve-month other financing activities. Sequentially, it fell 76.5% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Other financing activities amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Other financing activities grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +33.3% toward the trailing-twelve-month pace of +1924.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (33M) USD
- Year-over-year change
- +35.3%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33M) | +35.3% |
| FY2024 | 2024-12-31 | (51M) | -121.7% |
| FY2023 | 2023-12-31 | (23M) | +52.1% |
| FY2022 | 2022-12-31 | (48M) | +67.6% |
| FY2021 | 2021-12-31 | (148M) | — |
Other Financing Activities vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's LTM Jun 2026 other financing activities of $602M is the largest of the 11 companies compared; the peer median is $2.75M.
- Its year-over-year change of +1924.2% is the highest of 11, against a peer median of -15.4%.
- Other financing activities amounts to 2.3% of revenue for SYK, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $602M | +1924.2% | -11.7% | 2.3% | |
| LTM Jul 2026 | $525M | +630.3% | — | 1.4% | |
| LTM Jun 2026 | $314M | +890.5% | — | 3.7% | |
| LTM Mar 2026 | $39.39M | +13.1% | -31.4% | 2.9% | |
| LTM Jun 2026 | $37.92M | -55.6% | — | 1.2% | |
| FY2025 | $17M | +102.4% | — | 0.3% | |
| LTM Mar 2026 | $15.8M | -6.4% | -8.0% | 1.0% | |
| LTM Apr 2026 | $6.75M | -36.5% | — | 0.3% | |
| LTM Mar 2026 | $5.34M | -24.5% | +48.4% | 0.6% | |
| LTM Mar 2026 | $164K | -99.6% | — | 0.0% | |
| LTM Mar 2026 | $142K | -103.5% | — | 0.1% | |
| Peer median (excluding SYK) | $2.75M | -15.4% | -8.0% | 0.8% | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Depreciation & Amortization | 990M | 998M | 1.03B | 1.05B | 1.19B |
| Deferred Income Tax | (237M) | 58M | (206M) | (370M) | 392M |
| Stock-Based Compensation | 171M | 168M | 205M | 229M | 243M |
| Change in Working Capital | 279M | (732M) | (500M) | (683M) | (373M) |
| Accounts Receivables | (377M) | (579M) | (175M) | (321M) | 127M |
| Inventory | (189M) | (762M) | (797M) | (206M) | (297M) |
| Accounts Payables | 329M | 290M | 77M | 192M | 94M |
| Other Working Capital | 516M | 319M | 395M | (348M) | (297M) |
| Other Non-Cash Items | 66M | (226M) | 19M | 1.02B | 343M |
| Operating Cash Flow | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B |
| Capital Expenditures | (525M) | (588M) | (575M) | (755M) | (761M) |
| Acquisitions (Net) | (339M) | (2.56B) | (390M) | (1.63B) | (4.8B) |
| Purchases of Investments | (49M) | (52M) | (52M) | (808M) | 0 |
| Sales of Investments | 55M | 240M | 54M | 148M | 750M |
| Other Investing Activities | (1M) | 39M | 1M | 43M | (60M) |
| Investing Cash Flow | (859M) | (2.92B) | (962M) | (3B) | (4.87B) |
| Debt Repayment | (1.15B) | 472M | (277M) | 940M | 1.58B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (114M) | (122M) | (155M) | (195M) | (149M) |
| Dividends Paid | (950M) | (1.05B) | (1.14B) | (1.22B) | (1.28B) |
| Other Financing Activities | (148M) | (48M) | (23M) | (51M) | (33M) |
| Financing Cash Flow | (2.37B) | (749M) | (1.59B) | (525M) | 113M |
| Effect of Forex Changes | (38M) | (51M) | (28M) | (36M) | 68M |
| Net Change in Cash | 1M | (1.1B) | 1.13B | 681M | 359M |
| Free Cash Flow | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.